-transparent.png){kind=logo}
The National Cancer Institute of Canada Clinical Trials Group undertook a phase II study of 2'-deoxycoformycin in patients with metastatic renal cell carcinoma. When 2'-deoxycoformycin 4 mg/m2 was administered intravenously weekly for three weeks then every two weeks no significant antitumor activity was noted in 19 evaluable patients. Toxic effects experienced were as expected, consisting primarily of nausea/vomiting, anorexia, and lethargy. It is concluded that 2'-deoxycoformycin at this dose and schedule has no clinical activity in the treatment of metastatic renal cell carcinoma.
Related Publications
P Venner, and
E A Eisenhauer, and
R Wierzbicki, and
J Johnston
June 1986,
Cancer treatment reports,
P Venner, and
E A Eisenhauer, and
R Wierzbicki, and
J Johnston
October 1986,
Cancer treatment reports,
P Venner, and
E A Eisenhauer, and
R Wierzbicki, and
J Johnston
July 1988,
Journal of the National Cancer Institute,
P Venner, and
E A Eisenhauer, and
R Wierzbicki, and
J Johnston
February 1994,
Annals of oncology : official journal of the European Society for Medical Oncology,
P Venner, and
E A Eisenhauer, and
R Wierzbicki, and
J Johnston
August 1986,
Cancer treatment reports,
P Venner, and
E A Eisenhauer, and
R Wierzbicki, and
J Johnston
October 2007,
Investigational new drugs,
P Venner, and
E A Eisenhauer, and
R Wierzbicki, and
J Johnston
November 1986,
Cancer treatment reports,
P Venner, and
E A Eisenhauer, and
R Wierzbicki, and
J Johnston
September 1988,
Investigational new drugs,
P Venner, and
E A Eisenhauer, and
R Wierzbicki, and
J Johnston
February 1996,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
P Venner, and
E A Eisenhauer, and
R Wierzbicki, and
J Johnston
January 1987,
Cancer treatment reports,
